ZENITH DRUGS LIMIT — Quarterly Results & Earnings

₹41.00

+0.00%

Profit Growth YoY-55.24%Latest quarter

Sales Growth YoY15.56%Latest quarter

Sales CAGR 5Y11.10%5 year compound

Profit CAGR 5Y16.61%5 year compound

📋

Quarterly Performance

YoY Profit Growth-55.24%

🔴 Significant decline

YoY Sales Growth+15.56%

✅ Strong growth

OPM 5Y Average

Operating profit margin

9.94%

EPS Growth 5Y

N/A

Interest Coverage

Higher = safer debt servicing

2.27

ROE

11.11%

ROCE

12.90%

💡

Growth Analysis

ZENITH DRUGS LIMIT reported YoY profit growth of -55.24% and revenue growth of 15.56% in the latest quarter. Significant profit decline — requires close monitoring. Over 5 years, sales compounded at 11.10% and profits at 16.61% annually. Consistent growth over 4-8 quarters is more meaningful than any single quarter. Educational data only.

More on ZENITH DRUGS LIMIT

Overview Financials PE History Shareholding Quarterly Balance Sheet P&L Cash Flow Pharmaceuticals Stocks Screener

Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.